GlassScriptPhysician profile
Ryan Gilbert Michaud
NPI 1801935895
$30,481.30
in general payments reported to CMS, 2019-2025
36 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,595 · 2020: $4,146 · 2021: $8,249 · 2022: $6,654 · 2023: $1,681 · 2024: $3,603 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,837.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $26,594.13 | 2019-2025 | Proclaim, Octrode, Ionicrf |
| Boston Scientific Corporation | $1,437.53 | 2019-2025 | General - Pain Management |
| Medtronic USA, INC. | $287.80 | 2020 | |
| Globus Medical, INC. | $198.90 | 2025 | Omnia, Senza, Nevro |
| Collegium Pharmaceutical, INC. | $194.34 | 2019-2023 | Belbuca |
| Amgen INC. | $186.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $171.86 | 2019-2021 | |
| Nalu Medical, INC. | $169.23 | 2024-2025 | Nalu Neurostimulation System |
| Medtronic, INC. | $163.79 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Zynex Medical, INC. | $141.82 | 2025 | Nexwave |
| Grt US Holding, INC. | $97.23 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $68.85 | 2025 | |
| Orexo US, INC. | $67.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.89 | 2022 | |
| Abbvie INC. | $64.26 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $62.51 | 2019-2021 | |
| Si-Bone, INC. | $57.56 | 2022-2023 | |
| Scilex Pharmaceuticals INC. | $48.67 | 2019-2020 | |
| Ibsa Pharma INC. | $34.73 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.97 | 2021 | |
| Lilly USA, LLC | $29.52 | 2019-2022 | |
| Depuy Synthes Sales INC. | $27.88 | 2020 | |
| Tersera Therapeutics LLC | $26.08 | 2021 | |
| Spinal Simplicity, LLC | $22.01 | 2024 | Ha Minuteman G3-R |
| Averitas Pharma INC. | $21.27 | 2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2019 | |
| Zyla Life Sciences, INC. | $20.74 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.00 | 2021 | |
| Radius Health, INC. | $18.89 | 2019 | |
| Horizon Therapeutics Plc | $18.37 | 2022 | |
| Nevro Corp. | $17.17 | 2024 | Senza |
| Kaleo, INC. | $16.58 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.39 | 2021 | |
| Curonix LLC | $14.06 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pernix Therapeutics Holdings, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Michaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.